Avraham Pharmaceuticals reports interim Alzheimer’s trial success

News from the web:

Avraham Pharmaceuticals Ltd.The interim report on ladostigil’s safety profile found no serious or exceptional side effects, so the trial can continue from the safety aspect. The interim results also showed a positive trend in the drug’s efficacy. The interim results are based on 179 patients, 66 of whom have undergone six months of therapy. The company added that the number of patients planned for the study was enough to provide statistically meaningful final results, and the expert panel therefore recommends pursuing the study. The company expects to complete the trial and obtain the results by the end of the year.

Read all about it HERE